相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Emerging drugs for postmenopausal osteoporosis
E. Michael Lewiecki
EXPERT OPINION ON EMERGING DRUGS (2009)
Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women
David F. Archer et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2009)
Designing the ideal selective estrogen receptor modulator-an achievable goal?
Hugh S. Taylor
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2009)
Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis
JoAnn V. Pinkerton et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2009)
Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis
Catherine MacLean et al.
ANNALS OF INTERNAL MEDICINE (2008)
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
Stuart L. Silverman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study
Paul D. Miller et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women
Elizabeth Barrett-Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
Victor G. Vogel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society
Bruce Ettinger et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2006)
Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women
S Ronkin et al.
OBSTETRICS AND GYNECOLOGY (2005)
Benefit-risk assessment of raloxifene in postmenopausal osteoporosis
A Cranney et al.
DRUG SAFETY (2005)
Safety and adverse effects associated with raloxifene: Multiple outcomes of raloxifene evaluation
D Grady et al.
OBSTETRICS AND GYNECOLOGY (2004)
Continuing outcomes relevant to evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene
S Martino et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis
A Fontana et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2003)
Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study
SR Goldstein et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2002)
Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy
P Alexandersen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
分享论文
